Tirzepatide (5mg) Dosage Protocol
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It represents a novel "twincretin" approach.
Add 2.0 mL bacteriostatic water → 2.5 mg/mL
2.5mg-15mg once weekly (dose escalation required)
At 2.5 mg/mL: 10 units = 0.25mg, 40 units = 1mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 2.5mg weekly | 100 units (1.0 mL) |
| Weeks 5-8 | 5mg weekly | New vial or 2x dose |
| Weeks 9-12 | 7.5mg weekly | Escalate as tolerated |
| Weeks 13-16 | 10mg weekly | Escalate as tolerated |
| Week 17+ | 12.5-15mg weekly | Maximum maintenance |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall to prevent foaming
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. The SURMOUNT-1 trial demonstrated 15mg weekly resulted in average 18% body weight loss over 72 weeks. The dual mechanism provides enhanced metabolic effects compared to GLP-1 agonists alone.
- FDA-approved for weight management and type 2 diabetes
- Superior weight loss compared to GLP-1 agonists in trials
- Dual GIP/GLP-1 mechanism for enhanced efficacy
- Once-weekly dosing convenience
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216
- FDA Prescribing Information - Zepbound (tirzepatide) injection
- Frias JP, et al. Efficacy and tolerability of tirzepatide. Diabetes Obes Metab. 2020;22(6):938-946
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Protect from light during storage
- •Escalate dose in 2.5mg increments every 4 weeks minimum
- •Common side effects: nausea, diarrhea, decreased appetite
- •Contraindicated in personal/family history of MTC
- •Do not use with other GLP-1 receptor agonists
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.